Navigation Links
Gene variation affects tamoxifen's benefit for breast cancer

One of the most commonly prescribed drugs for breast cancer, tamoxifen, may not be as effective for women who inherit a common genetic variation, according to researchers at the University of Michigan and the Mayo Clinic. The genetic variation affects the level of a crucial enzyme that activates tamoxifen to fight breast cancer.

The study, co-led by researcher James Rae, Ph.D., at the University of Michigan Comprehensive Cancer Center and Matthew Goetz, M.D., an oncologist at the Mayo Clinic, tested the most common genetic variant responsible for lowering the CYP2D6 enzyme, and found that women with this genetic variant were almost twice as likely to see their breast cancer return. Up to 10 percent of women inherit this genetic trait.

Their findings are published in the Dec. 20 issue of The Journal of Clinical Oncology.

"Our group has shown that CYP2D6 is responsible for activating tamoxifen to a metabolite called endoxifen that is nearly 100 times more potent as an anti-estrogen than tamoxifen itself," says Rae, research assistant professor of internal medicine at the U-M Medical School. "Our study suggests that women who inherit a genetic variant in the CYP2D6 gene appear to be at higher risk of relapse when treated with five years of tamoxifen."

Researchers at the U-M Comprehensive Cancer Center were among the group to discover CYP2D6 metabolizes tamoxifen, and they are leading ongoing work looking at how genetic differences affect women's response to tamoxifen. Their research has also found the antidepressant drug Paxil can prevent tamoxifen from being activated, while the antidepressant drug Effexor does not. These drugs, selective serotonin reuptake inhibitors or SSRI's, are often used to treat hot flashes, a common side effect of tamoxifen.

In this current study of 256 women with breast cancer, researchers also found that women with the CYP2D6 variant were less likely to have hot flashes. Any hot flashes among this group tended to be less severe, suggesting that this side effect could predict the gene variation.

Further studies are needed, but researchers hope one day this finding may lead to a genetic test that could help doctors determine which women are most likely to benefit from tamoxifen. This type of test is not currently offered clinically.

Rae and Daniel F. Hayes, M.D., director of breast oncology at the U-M Comprehensive Cancer Center, are part of the Pharmacogenetics Research Network, a multidisciplinary research group conducting a prospective clinical trial to confirm whether genetic testing can be used to identify patients likely to respond to endocrine therapy, including tamoxifen. This group is led by David A Flockhart, M.D., Ph.D. at Indiana University School of Medicine.

More than 210,000 women in the United States will develop breast cancer. Approximately 70 percent of these cancers are fueled by estrogen, many of which are treated with tamoxifen, a drug designed to block the effects of estrogen in breast tissue. The findings from this trial were derived from a large North Central Cancer Treatment Group study in which women were treated with tamoxifen, a pill that is taken daily, for a total of five years.

Additional authors included the following researchers from the Mayo Clinic Cancer Center: Vera Suman, Ph.D.; Stephanie Safgren; Matthew Ames, Ph.D.; Daniel Visscher, M.D.; Carol Reynolds, M.D.; Fergus Couch, Ph.D.; Wilma Lingle, Ph.D.; and James Ingle, M.D., in Rochester, Minn.; and Edith Perez, M.D., in Jacksonville, Fla.; David Flockhart, M.D., Ph.D., and Zeruesenay Desta, Ph.D., both from Indiana University are also co-authors.


'"/>

Source:University of Michigan Health System


Related biology news :

1. Gene variations explain drug dose required to control seizures
2. Survival of heart patients on beta-blockers varies greatly with genetic variation
3. Genetic variation alters response to common anti-clotting drug
4. Studies on human genome variation provide insight into disease
5. New discovery: Molecular variation in one gene affects the growth of natural populations
6. Researchers map of genetic variations implicated in disease
7. Gene variation increases SIDS risk in African Americans
8. Chimpanzee study reveals genome variation hotspots
9. A new kind of mutation could explain numerous phenotypic variations in various species
10. International team analyzes human genetic variation in key immune region
11. New technology used to construct the first map of structural variation in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2016)... , March 29, 2016 ... "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are pleased to ... ink used in a variety of writing instruments, ensuring ... of originally created collectibles from athletes on LegacyXChange will ... analysis of the DNA. Bill Bollander ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
(Date:3/21/2016)... Unique technology combines v ... security   Xura, Inc. ... digital communications services, today announced it is working alongside ... customers, particularly those in the Financial Services Sector, the ... within a mobile app, alongside, and in combination with, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, ... microbial test has received AOAC Research Institute approval 061601. , “This is another ... year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel ...
Breaking Biology Technology: